Epizyme is leading the creation of small molecule histone methyltransferase
inhibitors (HMTi), a new class of personalized therapeutics for the treatment
of patients with genetically defined cancers, based on breakthroughs in the
field of epigenetics. Genetic alterations in HMTs, a family of epigenetic
enzymes, drive multiple human diseases. Our approach represents the future of
healthcare by matching better medicines with the right patients.